NeOnc Technologies Holdings, Inc.

Stage 4 · Declining · week 27

As of Oct 22, 2026, NeOnc Technologies Holdings is in Stage 4, the downtrend phase, now in week 27 (since Apr 17, 2026). It closed at $2.95, 75.1% below its 52-week high and below its 200-day average, which is falling.

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. More about the company

$2.95

+1.72% today

$85.0M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NTHI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-03-26 → 2026-10-22

S? 41w

S2 7w

S4 27w

2025-03-262026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S3 5w → S2 7w → S3 3w → S4 27w current

Total tracked: 82 weeks across 5 stage runs.

NTHI among Biotechnology422nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…422	NTHINeOnc Technologies Holdings, Inc.	Stage 4 · wk 27	16	−8.4%

vs 52W High

-75.1%

$2.53 lo$11.83 hi

75.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 27

1w13w26w

Week 27, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-47.9%

200 DMA: $5.66 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.32x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-8.4%

-14.0%

-38.4%

YTD

-66.8%

-68.8%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 27 · Vol 0.32x

2026-10-21S4

Wk 26 · Vol 0.45x

2026-10-20S4

Wk 26 · Vol 0.42x

2026-10-19S4

Wk 26 · Vol 0.47x

2026-10-16S4

Wk 26 · Vol 0.44x

2026-10-15S4

Wk 26 · Vol 0.45x

2026-10-14S4

Wk 25 · Vol 0.57x

2026-10-13S4

Wk 25 · Vol 0.32x

2026-10-12S4

Wk 25 · Vol 0.42x

2026-10-09S4

Wk 25 · Vol 0.72x

2026-10-08S4

Wk 25 · Vol 1.13x

2026-10-07S4

Wk 24 · Vol 1.03x

Moving averages & range

50 DMA

$3.65

200 DMA

$5.66

52W High

$11.83

52W Low

$2.53

5D Low

$2.70

Resistance levels (recent highs)

20d High

$3.41

60d High

$5.53

120d High

$6.49

250d High

$11.83

Next resistance

+15.4%

to 20d High

Dividend Yield

0.00%

P/B -3.4

NeOnc Technologies Holdings: quick answers

What stage is NeOnc Technologies Holdings in?

As of Oct 22, 2026, NeOnc Technologies Holdings (NTHI) is in Stage 4, the downtrend phase. It entered Stage 4 on Apr 17, 2026 and is in week 27. What the four stages mean

Is NeOnc Technologies Holdings in an uptrend?

No. NeOnc Technologies Holdings is in a Stage 4 downtrend. It trades 47.9% below its 200-day average, which is falling.

How far is NeOnc Technologies Holdings from its 52-week high?

NeOnc Technologies Holdings closed at $2.95 on Oct 22, 2026, 75.1% below its 52-week high of $11.83. Its 52-week low is $2.53.

How has NeOnc Technologies Holdings performed over the past year?

As of Oct 22, 2026, NeOnc Technologies Holdings is down 68.8% over the past year and down 66.8% so far in 2026.

Which sector and industry is NeOnc Technologies Holdings in?

NeOnc Technologies Holdings is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.